Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Dissecting the Enzyme Mechanics and Ligand Binding of Kinetoplastid Ribonucleic Acid Editing Ligase 1 Protein
EF 2025-26
Résumé
Trypanosomatids (Trypanosoma Brucei, Trypansoma Cruzi, Leishmania spp.) cause parasitic diseases globally. They cause African sleeping sickness, Chagas disease, and leishmaniasis respectively. Together, these three parasites affect approximately 20 million people worldwide, and thanks to global warming we are seeing more cases appearing in north America and Europe. Current drugs available to patients are highly toxic chemotherapeutics with resistance on the rise. A validated target for drug discovery is the Kinetoplastid RNA Editing Ligase 1 (KREL1) which is homologous between all three diseases and has no mammalian counterpart, making it a highly attractive drug target. It is essential to parasite survival as is responsible ligating spliced mRNA via the editosome complex for mitochondrial proteins which the parasite cannot survive without in vivo. Our lab has made strides in discovering novel compounds that may prove useful as new therapeutics, however two interesting cases inhibited the complete Editosome complex, but not rKREL1. The goal of this research project is thus to dissect the enzyme kinetics and ligand binding mechanics of KREL1. We hypothesize that the associated proteins in the complex confer a different ATP binding pocket to KREL1 that is spatially different from the recombinant form that does not include the associated proteins. To test this, we will first determine the mechanism of inhibition of our two compounds of interest (Dubbed MRS2289/2295). We then also plan to do in vivo parasite survival studies against our compounds as well as photolinker coupled to mass spectrometry studies to determine the exact binding pocket and critical amino acids. Mutagenesis studies in this pocket will further confirm our findings.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573003
Name
Tsoklis Thomas A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Dissecting the Enzyme Mechanics and Ligand Binding of Kinetoplastid Ribonucleic Acid Editing Ligase 1 Protein
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Editosome; Inhibitors; Insight; Interaction; Kinetics; Mechanism; Structure; Therapeutics; Treatment; Trypanosomatids
Abstract
Trypanosomatids (Trypanosoma Brucei, Trypansoma Cruzi, Leishmania spp.) cause parasitic diseases globally. They cause African sleeping sickness, Chagas disease, and leishmaniasis respectively. Together, these three parasites affect approximately 20 million people worldwide, and thanks to global warming we are seeing more cases appearing in north America and Europe. Current drugs available to patients are highly toxic chemotherapeutics with resistance on the rise. A validated target for drug discovery is the Kinetoplastid RNA Editing Ligase 1 (KREL1) which is homologous between all three diseases and has no mammalian counterpart, making it a highly attractive drug target. It is essential to parasite survival as is responsible ligating spliced mRNA via the editosome complex for mitochondrial proteins which the parasite cannot survive without in vivo. Our lab has made strides in discovering novel compounds that may prove useful as new therapeutics, however two interesting cases inhibited the complete Editosome complex, but not rKREL1. The goal of this research project is thus to dissect the enzyme kinetics and ligand binding mechanics of KREL1. We hypothesize that the associated proteins in the complex confer a different ATP binding pocket to KREL1 that is spatially different from the recombinant form that does not include the associated proteins. To test this, we will first determine the mechanism of inhibition of our two compounds of interest (Dubbed MRS2289/2295). We then also plan to do in vivo parasite survival studies against our compounds as well as photolinker coupled to mass spectrometry studies to determine the exact binding pocket and critical amino acids. Mutagenesis studies in this pocket will further confirm our findings.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tsoklis, Thomas A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~